<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888301</url>
  </required_header>
  <id_info>
    <org_study_id>15-000246</org_study_id>
    <secondary_id>NCI-2016-00210</secondary_id>
    <secondary_id>15-000246</secondary_id>
    <nct_id>NCT02888301</nct_id>
  </id_info>
  <brief_title>18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions</brief_title>
  <official_title>The Biodistribution of [18F]-Clofarabine in Cancer Patients Before and After Interventions That Increase the Activity of Deoxycytidine Kinase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed&#xD;
      tomography (CT) in imaging patients with cancer before and after treatment with a therapy&#xD;
      that activates the patient's immune system (immunotherapy). PET/CT scans give detailed&#xD;
      pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive&#xD;
      substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly&#xD;
      expressed in activated immune cells, making them light up during PET/CT scans. Doctors also&#xD;
      want to know how 18F-clofarabine is distributed throughout the body before and after&#xD;
      treatment with immunotherapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether positron emission tomography (PET) using the new imaging agent&#xD;
      18F-clofarabine can be used for imaging cancer, and whether interventions that activate the&#xD;
      immune system can change the biodistribution of 18F-clofarabine.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive 18F-clofarabine intravenously (IV) and undergo PET/CT scan at baseline and&#xD;
      2-4 weeks after completion of immunotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 12, 2015</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>18F-clofarabine concentration in cancer tissue</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 18F-clofarabine biodistribution</measure>
    <time_frame>Baseline to up to 4 weeks</time_frame>
    <description>For the biodistribution studies, regions of interest will be drawn on images of liver, kidney, bladder, heart, lung and blood pool to obtain regional activity count rates. Standardized uptake values (SUV = count activity per ml within region of interest (MBq-1)/(injected dose [MBq]/body weight [kgx1000]) will be calculated for different organs and for regions of tumor. Further, regional target to background count activity ratios will be established.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Basic science (18F-clofarabine biodistribution)</arm_group_label>
    <description>Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo 18F-clofarabine PET/CT</description>
    <arm_group_label>Basic science (18F-clofarabine biodistribution)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fluorine F 18 Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Basic science (18F-clofarabine biodistribution)</arm_group_label>
    <other_name>18F-CA</other_name>
    <other_name>18F-Clofarabine</other_name>
    <other_name>[18F]-Clofarabine</other_name>
    <other_name>Cl-18F-ara-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 18F-clofarabine PET/CT</description>
    <arm_group_label>Basic science (18F-clofarabine biodistribution)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult cancer patients under treatment using immune system activating interventions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)&#xD;
&#xD;
          -  No restrictions based on gender or racial/ethnic background&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing age will have to undergo a pregnancy test that will be provided&#xD;
             free of charge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Allen-Auerbach</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

